Immix Biopharma, Inc.

Sterically-optimized BCMA CAR-T cell therapy

IMMX · Nasdaq · United States

Public Market Listing

IMMXNasdaq

Nasdaq primary exchange listing

Live quotes, historical charts, and market capitalization for Immix Biopharma, Inc. are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 1/2
BCMA (TNFRSF17)Cell therapy
Multiple MyelomaAmyloidosis
AL Amyloidosis

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

14 December 2026PresentationNXC-201NEXICART-2 45-patient interim results oral presentation at ASH 2026
US · Immix Biopharma, Inc. · Source ↗

Recent

29 September 2026Topline resultNXC-201NEXICART-2 interim update: 89% (40/45) IRC-assessed CR rate
US · Immix Biopharma, Inc. · Source ↗

Financial reports

Quarterly & interim (2)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$5.5M$320M—report ↗
View 1 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$5.3M$225M—report ↗

Annual history (1 year)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY——$94M—-$24M operating cash flowreport ↗